- Conditions
- Insulin Sensitivity
- Interventions
- Glucagon Infusion, Saline
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 470
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes Mellitus, Healthy
- Interventions
- GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Diabetes Type I
- Interventions
- sitagliptin, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Adult Obesity, Weight Management
- Interventions
- ECC4703, Placebo, Semaglutide
- Drug
- Lead sponsor
- Eccogene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Anaheim, California • Los Alamitos, California + 11 more
- Conditions
- Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Obesity, Overweight or Obesity
- Interventions
- MET097, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Hollywood, Florida • Tampa, Florida • Decatur, Georgia + 2 more
- Conditions
- Crohn Disease
- Interventions
- Tirzepatide, Mediterranean diet
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 14
- States / cities
- Buena Park, California • Fresno, California • San Jose, California + 11 more
- Conditions
- Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
- Interventions
- GLP-1 Receptor Agonists
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes
- Interventions
- Epic-Based Clinician Notification, Usual Care
- Other
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Plano, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide (1 Mg Dose), Placebo
- Drug
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Obesity, Overweight, Taste Perception, Olfaction, Eating Behavior, Appetite
- Interventions
- Not listed
- Lead sponsor
- Purdue University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- West Lafayette, Indiana
- Conditions
- Type 1 Diabetes
- Interventions
- Intradermal injection, Subcutaneous injection
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exendin9
- Drug
- Lead sponsor
- Blandine Laferrere
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Does the Vagus Nerve Mediate the Effects of Xenin-25
- Interventions
- Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus, Type 1, Endothelial Dysfunction
- Interventions
- Dulaglutide, Placebo
- Drug
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- Bionic Pancreas, Usual Care
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glucose Homeostasis
- Interventions
- Placebo, Januvia
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Interventions
- aleniglipron, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more
- Conditions
- Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Ranolazine, Placebo, Exenatide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Miami, Florida • Orlando, Florida
- Conditions
- Obesity
- Interventions
- bremelanotide, tirzepatide
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Placebo, taspoglutide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Woodstock, Georgia • Chicago, Illinois + 7 more
- Conditions
- Coronary Artery Disease, Diabetes Mellitus Type 2
- Interventions
- Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota